Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Berman

Plastic Surgery within the Head & Neck Beverly Hills, CA Medical Doctor

NPI 1427172709 CMS profile 337004

9001 Wilshire Blvd, Suite 100, Beverly Hills, CA 90211

Open in the dashboard

General payments

$3,645

147 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Berman of Beverly Hills, CA is reported in the CMS Open Payments database as having received $3,645 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Plastic Surgery within the Head & Neck profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $509 20
2024 General $479 19
2023 General $803 32
2022 General $799 29
2021 General $447 21
2020 General $388 17
2019 General $221 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Berman
  • Plastic Surgery within the Head & Neck median
  • Middle half of Plastic Surgery within the Head & Neck
  • National median

In program year 2025, general payments to Andrew Berman were reported at $509. Among 399 Plastic Surgery within the Head & Neck profiles paid that year, the median was $237 and the middle half received between $103 and $520.

Show as a table
Year Andrew Berman Plastic Surgery within the Head & Neck median Middle half National median
2019 $221 $200 $82–$550 $163
2020 $388 $120 $46–$330 $114
2021 $447 $166 $60–$382 $132
2022 $799 $208 $83–$530 $149
2023 $803 $202 $77–$538 $160
2024 $479 $260 $99–$645 $164
2025 $509 $237 $103–$520 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $989 35 payments
  2. Novartis Pharmaceuticals Corporation $438 16 payments
  3. Genzyme Corporation $309 12 payments
  4. Amgen Inc. $222 9 payments
  5. OptiNose US, Inc. $213 10 payments
  6. Hikma Pharmaceuticals USA $199 10 payments
  7. Incyte Corporation $197 8 payments
  8. Octapharma USA, Inc. $179 7 payments
  9. Merz North America, Inc. $142 7 payments
  10. GlaxoSmithKline, LLC. $100 4 payments
  11. Other $657 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,645 147 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $848 29 payments
  2. DUPIXENT Immunology $467 19 payments
  3. XOLAIR $252 9 payments
  4. TEZSPIRE $222 9 payments
  5. Xhance $213 10 payments
  6. Ryaltris $199 10 payments
  7. OPZELURA $197 8 payments
  8. Xeomin $142 7 payments
  9. DUPIXENT Immunology And Inflammation $142 6 payments
  10. SPIRIVA RESPIMAT $118 6 payments
  11. Other $1,114 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$20,844

Medicare's payments for the services billed

Medicare patients

160

Average age 75

Services billed

342

77 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 56%
Ischemic heart disease 48%
Diabetes 28%
Osteoporosis 23%
Chronic kidney disease 21%
Depression 20%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $79
  • Regeneron Healthcare Solutions, Inc. $28
$107 — —
Ryaltris
  • Hikma Pharmaceuticals USA $102
$102 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $66
  • Genentech USA, Inc. $24
$91 — —
TEZSPIRE
  • Amgen Inc. $50
  • AstraZeneca Pharmaceuticals LP $23
$72 — —
CUTAQUIG
  • Octapharma USA, Inc. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery within the Head & Neck in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record